Fernando Fernandez - BiocardiaInc Director
| BCDA Stock | USD 0.37 0.01 2.78% |
Director
Mr. Fernando L. Fernandez is a Director of the BIOCARDIA, INC. He was appointed to our board of directors immediately following the completion of the Merger in October 2016. Mr. Fernandez has served as the Market Vice President and Chief Financial Officer of the Care Delivery segment of Humana, Inc., a health and wellbeing company, since December 2012. From June 2004 to December 2012, Mr. Fernandez served as the Senior Vice President of Finance and Chief Financial Officer of Continucare Corporationrationration, a medical care service company. Mr. Fernandez spent his early career in public accounting and finance functions at other companies, including Whitman Education Group, Inc., FrostNevada LP, and PriceWaterhouseCoopers LLP. He has previously served on the Board of Directors of ERBA Diagnostics, Inc., Bristol Bank and SSE Investments, Inc since 2016.
| Age | 56 |
| Tenure | 8 years |
| Address | 320 Soquel Way, Sunnyvale, CA, United States, 94085 |
| Phone | 650 226 0120 |
| Web | https://www.biocardia.com |
BiocardiaInc Management Efficiency
The company has return on total asset (ROA) of (1.1389) % which means that it has lost $1.1389 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.0362) %, meaning that it created substantial loss on money invested by shareholders. BiocardiaInc's management efficiency ratios could be used to measure how well BiocardiaInc manages its routine affairs as well as how well it operates its assets and liabilities. At present, BiocardiaInc's Return On Capital Employed is projected to increase based on the last few years of reporting. The current year's Return On Equity is expected to grow to 7.58, whereas Return On Tangible Assets are projected to grow to (3.68). At present, BiocardiaInc's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 265.9 K, whereas Total Assets are forecasted to decline to about 2.8 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Robert Stein | Protagenic Therapeutics | 65 | |
| Brian Corvese | Protagenic Therapeutics | N/A | |
| Julie Hill | AN2 Therapeutics | 69 | |
| Yan MBA | Adagene | 49 | |
| Kerry Clark | AN2 Therapeutics | 63 | |
| David Welch | Rezolute | 56 | |
| Lewis Hay | AN2 Therapeutics | 60 | |
| Robert Dixon | AN2 Therapeutics | 60 | |
| Ramiro Peru | AN2 Therapeutics | 60 | |
| Hoyoung Huh | Rezolute | 47 | |
| Antonio Neri | AN2 Therapeutics | 49 | |
| Tae Kim | Rezolute | 34 | |
| Samir Patel | Rezolute | 46 | |
| John Short | AN2 Therapeutics | 70 | |
| George Schaefer | AN2 Therapeutics | 70 | |
| Gilbert Labrucherie | Rezolute | 44 | |
| William Ryan | AN2 Therapeutics | 71 | |
| Elizabeth Tallett | AN2 Therapeutics | 67 | |
| Joshua Silverman | Protagenic Therapeutics | 47 | |
| Gregory Ekizian | Protagenic Therapeutics | 51 | |
| TsungShann EMBA | ABVC Biopharma | 70 | |
Management Performance
| Return On Equity | -7.04 | ||||
| Return On Asset | -1.14 |
BiocardiaInc Leadership Team
Elected by the shareholders, the BiocardiaInc's board of directors comprises two types of representatives: BiocardiaInc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BiocardiaInc. The board's role is to monitor BiocardiaInc's management team and ensure that shareholders' interests are well served. BiocardiaInc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BiocardiaInc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Altman, President CEO, Principal Executive Officer, Director | ||
| Edward Gillis, Senior Devices | ||
| Richard Allen, Vice President of quality | ||
| Mark Schwartz, Vice President - Clinical Affairs | ||
| Phil Pesta, Vice President - Operations | ||
| Ian McNiece, Chief Officer | ||
| Sujith MBBS, Chief Regulatory | ||
| Thomas Quertermous, Director | ||
| Richard Pfenniger, Director | ||
| Fernando Fernandez, Director | ||
| Simon Stertzer, Chairman of the Board | ||
| Allan Tessler, Director | ||
| Henricus Duckers, Chief Medical Officer | ||
| Sujith Shetty, Chief Regulatory | ||
| David McClung, Principal Financial and Accounting Officer, Vice President - Finance | ||
| Richard Krasno, Director | ||
| Jay Moyes, Director |
BiocardiaInc Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BiocardiaInc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.04 | ||||
| Return On Asset | -1.14 | ||||
| Operating Margin | (160.31) % | ||||
| Current Valuation | 9.84 M | ||||
| Shares Outstanding | 26.87 M | ||||
| Shares Owned By Insiders | 33.84 % | ||||
| Shares Owned By Institutions | 7.71 % | ||||
| Number Of Shares Shorted | 535.91 K | ||||
| Price To Earning | (11.00) X | ||||
| Price To Book | 10.67 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BiocardiaInc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BiocardiaInc's short interest history, or implied volatility extrapolated from BiocardiaInc options trading.
Pair Trading with BiocardiaInc
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BiocardiaInc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BiocardiaInc will appreciate offsetting losses from the drop in the long position's value.Moving against BiocardiaInc Stock
| 0.45 | PBH | Prestige Brand Holdings Financial Report 2nd of May 2024 | PairCorr |
| 0.45 | ANIP | ANI Pharmaceuticals Financial Report 13th of May 2024 | PairCorr |
| 0.44 | AVTE | Aerovate Therapeutics Financial Report 20th of May 2024 | PairCorr |
| 0.42 | OPT | Opthea | PairCorr |
| 0.41 | SUPN | Supernus Pharmaceuticals Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to BiocardiaInc could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BiocardiaInc when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BiocardiaInc - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BiocardiaInc to buy it.
The correlation of BiocardiaInc is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BiocardiaInc moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BiocardiaInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BiocardiaInc can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BiocardiaInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade BiocardiaInc Stock refer to our How to Trade BiocardiaInc Stock guide.Note that the BiocardiaInc information on this page should be used as a complementary analysis to other BiocardiaInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for BiocardiaInc Stock analysis
When running BiocardiaInc's price analysis, check to measure BiocardiaInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BiocardiaInc is operating at the current time. Most of BiocardiaInc's value examination focuses on studying past and present price action to predict the probability of BiocardiaInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BiocardiaInc's price. Additionally, you may evaluate how the addition of BiocardiaInc to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is BiocardiaInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BiocardiaInc. If investors know BiocardiaInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BiocardiaInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.55) | Revenue Per Share 0.023 | Quarterly Revenue Growth (0.88) | Return On Assets (1.14) | Return On Equity (7.04) |
The market value of BiocardiaInc is measured differently than its book value, which is the value of BiocardiaInc that is recorded on the company's balance sheet. Investors also form their own opinion of BiocardiaInc's value that differs from its market value or its book value, called intrinsic value, which is BiocardiaInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BiocardiaInc's market value can be influenced by many factors that don't directly affect BiocardiaInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BiocardiaInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if BiocardiaInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BiocardiaInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.